AprilBio Co

AprilBio Co LT Debt/Equity

Long-Term Debt to Equity Ratio of AprilBio Co (397030.KQ) as of Oct 31, 2026.

LT Debt/Equity

0.00

YoY

-64.95%

Last updated:

Long-Term Debt to Equity Ratio of AprilBio Co is 2024 0.00 . Long-Term Debt to Equity Ratio of AprilBio Co was 2023 0.00 . It decreases by -64.95% lower compared to the previous year.

The AprilBio Co LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2022
0.00 KRW
Jan 1, 2023
0.00 KRW
Jan 1, 2024
0.00 KRW
The AprilBio Co LT Debt/Equity history
YEARLT Debt/EquityYoY
0.00-64.95%
0.00+141.59%
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AprilBio Co Stock analysis

What does AprilBio Co do? AprilBio Co Ltd, headquartered in Chuncheon, South Korea, operates in the Health Care sector, specializing in biotechnology. The company focuses on developing long-acting proteins and antibody drugs, primarily engaged in R&D for innovative biopharmaceuticals including antibody therapeutics and long-acting recombinant protein pharmaceuticals. Listed on July 28, 2022, it employs 24 full-time staff in its research and development activities. AprilBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AprilBio Co stock

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio AprilBio Co since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's AprilBio Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — AprilBio Co

All Key Metrics — AprilBio Co